Intravesical anesthesia for bladder tissue biopsies. Comparison of two methods.

PURPOSE: To estimate the level of analgesia which can be obtained with simple intravesical instillation of ropivacaine in comparison to the combination of both instillation and subepithelial injection of the same agent. MATERIALS AND METHODS: Fifty-two patients were randomized in order that half (26) of them received simple intravesical instillation of ropivacaine (100 mL solution of ropivacaine in a concentration of 2 mg/mL) (Group A), whereas the other 26 patients received both intravesical instillation and subepithelial injection of 2 mL (4 mg) at the site of biopsy (Group B). In both groups, tissue samples were obtained from urinary bladder (number of biopsies from 3 to 4). The pain during the procedure was estimated by using the Visual Analogue Scale (VAS) which ranged from 0 to 10. RESULTS: The entire procedure was integrated with success in 50 out of 52 patients. The VAS score for the Group A ranged from 4 to 6 (mean 5.08), whereas for Group B from 1 to 3 (mean 1.6). (p<0.0001). Higher values of VAS score were recorded in males in both Groups (p<0.05). When complications of this method produced a slight bleeding (hematuria) in 6 patients (2 from group B and 4 from group A), they were treated with oral administration of fluids. Allergic reactions were not recorded. Hospitalization did not exceed 3 hours after the procedure. CONCLUSIONS: The analgesic effect that was obtained with the combination of intravesical instillation and subepithelial injection of ropivacaine provides a safe method of anesthesia for transurethral bladder biopsy.

Intravesical anesthesia for bladder tissue biopsies: comparison of two methods

PURPOSE: To estimate the level of analgesia which can be obtained with simple intravesical instillation of ropivacaine in comparison to the combination of both instillation and subepithelial injection of the same agent. MATERIALS AND METHODS: Fifty-two patients were randomized in order that half (26) of them received simple intravesical instillation of ropivacaine (100 mL solution of ropivacaine in a concentration of 2 mg/mL) (Group A), whereas the other 26 patients received both intravesical instillation and subepithelial injection of 2 mL (4 mg) at the site of biopsy (Group B). In both groups, tissue samples were obtained from urinary bladder (number of biopsies from 3 to 4). The pain during the procedure was estimated by using the Visual Analogue Scale (VAS) which ranged from 0 to 10. RESULTS: The entire procedure was integrated with success in 50 out of 52 patients. The VAS score for the Group A ranged from 4 to 6 (mean 5.08), whereas for Group B from 1 to 3 (mean 1.6). (p < 0.0001). Higher values of VAS score were recorded in males in both Groups (p < 0.05). When complications of this method produced a slight bleeding (hematuria) in 6 patients (2 from group B and 4 from group A), they were treated with oral administration of fluids. Allergic reactions were not recorded. Hospitalization did not exceed 3 hours after the procedure. CONCLUSIONS: The analgesic effect that was obtained with the combination of intravesical instillation and subepithelial injection of ropivacaine provides a safe method of anesthesia for transurethral bladder biopsy.

Modification of retropubic adenomectomy: improved hemostasis and outcome.

INTRODUCTION: Our modification is based on the employment of the ligation of both the deep dorsal penile vein (DDPV) and the lateral vesicoprostatic pedicles before enucleation of adenoma in retropubic adenomectomy, for treatment of bladder outflow obstruction due to large benign prostate hyperplasia (BPH). PATIENTS AND METHODS: From January 2004 till May 2005, 18 patients suffering from large BPH obstruction (mean value of adenoma 145.4 cm(3)) were operated with this modification. RESULTS: The mean hematocrit values preoperatively and 12 h postoperatively were 40 and 36.6%, respectively. Accordingly no patient required transfusion. Postoperative bladder complaints (pain, discomfort) were not mentioned. In 3/18 (16.7%) of the patients transient stress incontinence was observed after catheter removal and totally subsided in all of them at the 1-month follow up. DISCUSSION: This modification eliminates any possible source of bleeding and therefore converts an operation which is traditionally associated with blood loss to a totally bloodless procedure. Furthermore, the ligation of DDPV in association to retropubic adenomectomy may be proved helpful in a proportion of patients with impotence. CONCLUSION: In experienced hands, the employment of both DDPV ligation and transfixion of lateral vesicoprostatic pedicles may significantly optimise the postoperative results of retropubic adenomectomy.

Retroperitoneal anomalies in men with testicular germ cell tumours.

OBJECTIVES: To assess whether vascular and other retroperitoneal anomalies are more frequent during retroperitoneal lymph node dissection (RPLND) for metastatic testicular tumours (when retroperitoneal masses persist after chemotherapy) than would be expected, based on the initial observations from one centre with a large experience of RPLND in the UK. PATIENTS AND METHODS: A prospective series of 278 consecutive patients treated with RPLND for testicular tumours comprised the sample population. For each patient the presence or absence of four factors from the history was recorded. Each patient then underwent RPLND. During surgery, a template was constructed of the anatomy of the retroperitoneum and the information stored. Eight different retroperitoneal anatomical anomalies were identified in the sample population; the incidence of each was then compared with the largest available study of a normal population, and differences analysed statistically. RESULTS: Of the 278 patients who had RPLND, 55 had 59 anomalies (21%), found by history and as retroperitoneal vascular and urological anomalies; cryptorchidism was present in 7.6%, 9.5 times the incidence in the control population (P < 0.01). A left-sided inferior vena cava was present in 3.6% of patients, 21 times the incidence in the control population (P < 0.001); a retro-aortic left renal vein in 3.2%, four times that in the control population (P < 0.05); and ipsilateral renal agenesis had an incidence of 1% in the test population, 11 times greater than in the control population (P < 0.01). CONCLUSIONS: This prospective study of 278 RPLNDs provides evidence that some retroperitoneal anatomical anomalies are associated with testicular germ cell tumours. The link between maldescent and testicular tumours, rather than an isolated association, should be considered as part of a spectrum of retroperitoneal anomalies that occur in these men.

Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.

BACKGROUND: Although tumor grade and stage are the most accurate prognostic factors in the evaluation of transitional cell bladder cancer, they cannot always predict the true tumor biological potential since superficial tumors of the same stage and grade may have completely different clinical courses. This study was performed in order to examine whether p53, bcl-2 and Ki-67 have any validity in predicting the course of superficial bladder tumors, with high risk for recurrence or progression, over the traditional prognostic factors that are currently used. Furthermore, we investigated whether any one of these markers maintains its prognostic capability after one course of intravesical instillations of IFN gamma. MATERIALS AND METHODS: The immunohistochemical evaluation of bladder tumor specimens, that were obtained transurethrally for the expression of p53, bcl-2 and Ki-67, was performed in 58 patients. After meticulous selection of cut-off values for the expression of the aforementioned markers, twenty-eight patients were treated only with transurethral resection (TURBT only group) while 30 patients received adjuvantly intravesical instillations of interferon gamma. The times to first recurrence and progression were recorded during the follow-up period which ranged from 3 to 36 months (mean 11.7 months). The prognostic significance of tumor stage, grade, presence of CIS, p53, bcl-2 and Ki-67 in determining the risk for recurrence, was studied with both univariate (log-rank test) and multivariate (Cox regression) methods of analysis, separately for the TURBT only group of patients and for those who received instillations. The same analysis was employed for the risk of progression in the overall number of progressed patients. RESULTS: According to both uni- and multivariate analysis of the prognostic significance for tumor stage (T), grade (G), presence of CIS, p53, Ki-67 and bcl-2 in each group of patients, the Ki-67 index was the only independent prognostic factor for recurrence in patients treated with TURBT only (p = 0.0044 univariate, p = 0.031 multivariate). None of the factors which were studied proved to have prognostic significance for recurrence in the group of patients who received adjuvant intravesical instillation with the immunomodulating agent. Although in the univariate analysis all the studied parameters except tumor stage seem to be associated in a statistically significant manner with higher risk for progression, the multivariate analysis did not yield any independent significant prognosticator. The same evaluation was performed only for the patients with grade 2 disease (28) and yielded statistically significantly higher risk for recurrence, both in uni- (p = 0.0081) and in multivariate analysis (p = 0.044) only in the patients with overexpression of Ki-67 who were treated with TURBT alone. CONCLUSION: The Ki-67 proliferative index has an independent validity in predicting those patients with high risk superficial bladder tumors who may recur in a short follow-up period. A similar relationship of Ki-67 overexpression to progression was not detected. The expression of p53 and bcl-2 does not seem to offer any prognostic information in predicting either recurrence or progression over the prognostic factors that are currently used in clinical practice.